Press Releases Latest Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Press Releases Year None202420232022202120202019201820172016201520142013 Oct 04, 2023 Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA Sep 26, 2023 Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates Sep 25, 2023 Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility Sep 25, 2023 Theratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA Review Sep 20, 2023 Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023 Sep 18, 2023 Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update Sep 07, 2023 Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference Sep 05, 2023 Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights Aug 30, 2023 Theratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide Jul 31, 2023 Theratechnologies Completes 1-for-4 Reverse Stock Split First page « Previous page ‹ … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page › Last page » Displaying 51 - 60 of 379
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
Oct 04, 2023 Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA
Sep 26, 2023 Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
Sep 25, 2023 Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility
Sep 18, 2023 Theratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business Update
Sep 07, 2023 Theratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 30, 2023 Theratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide
